AI Terminal
Xbrane Biopharma
Declaration of Voting Results & Voting Rights Announcements • Jan 31, 2025
3128_rns_2025-01-31_de410bf3-1617-480b-be7b-ecd330ff6d4b.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
As of January 31, 2025, the total number of shares and votes in the Company amounts to 1.532.190.295. The Company's registered share capital amounts to SEK 343.495.707,488169.
Contacts
Martin Åmark, CEO E: [email protected]
Jane Benyamin, CFO/IR E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-01-31 08:00 CET.
Attachments
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.